Vol. 3 No. 3 (2023)
Reimbursement Reviews

Darolutamide (Nubeqa)

decorative image

Published March 28, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses darolutamide (Nubeqa), 300 mg, tablet, for oral use.
  • Indication: The treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel.